The Elderly ACS II Trial
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to compare reduced-dose prasugrel and standard dose clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS) and ST-elevation (STEMI) patients, undergoing early PCI. The primary endpoint of the trial will be the one-year composite of (all-cause)death, myocardial infarction, stroke and re-hospitalization due to cardiovascular reasons or bleeding.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Coronary Syndrome Coronary Arteriosclerosis Myocardial Ischemia Cardiovascular Diseases |
Drug: prasugrel Drug: Clopidogrel |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) |
- The composite of all-cause mortality, myocardial infarction (MI), disabling stroke and re-hospitalization for cardiovascular causes or bleeding within one year [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
- The composite of burden of recurrent cardiovascular (CV) events, CV mortality, all-cause mortality and MI, major bleeding, any stroke, total number of days spent in hospital. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
definition of major bleeding:
- Bleeding Academic Research Consortium (BARC) type 2 or 3 bleeding within 1 year (for bleedings occurring during index or subsequent hospitalizations)
· BARC type IV bleeding within 1 year
| Estimated Enrollment: | 2000 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | October 2016 |
| Estimated Primary Completion Date: | June 2016 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: prasugrel
prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
|
Drug: prasugrel
prasugrel 5 mg o.d.
Other Name: Efient
|
|
Active Comparator: clopidogrel
Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
|
Drug: Clopidogrel
75 mg o.d.
Other Name: Plavix
|
Eligibility| Ages Eligible for Study: | 75 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients >74 years of age hospitalized for an ACS, with or without STE, with an onset of symptoms during the previous 72 hours, and candidates to an early PCI.
- STEMI patients may be randomized upon first diagnosis, provided they do not meet any exclusion criteria. STEMI patients should not exceed 50 percent of the global population of the study
Eligible NSTEACS patients may be randomized after coronary angiography. To be eligible, NSTEACS patients must have at least one of the following characteristics:
- elevated troponin levels;
- diabetes mellitus;
- prior MI;
- at least one new ischemic episode while on standard treatment during the index hospitalization;
- ACS due to stent thrombosis.
Exclusion Criteria:
- History of stroke or transient ischemic attack (TIA)
- Gastrointestinal or genitourinary bleeding of clinical significance within 6 weeks prior to randomization.
- Hemoglobin level on admission <10 g/dl, unless this is considered to be secondary to renal dysfunction or known myelodysplasia.
- Secondary causes of acute myocardial ischemia.
- Known current platelet count < 90,000 cells/mL.
- Ongoing oral anticoagulant treatment or an INR known to be >1.5 at the time of screening.
- Concomitant severe obstructive lung disease, malignancy or neurologic deficit limiting follow-up or adherence to the study protocol.
- Participation in any phase of another clinical research study involving the evaluation of another investigational drug or device within 30 days prior to randomization
- Inability to give at least verbal informed consent to the study.
- Contraindications to the use of clopidogrel or prasugrel as per package leaflet.
Contacts and Locations| Contact: Stefano Savonitto, MD | +39-0522-296361 | stefano.savonitto@asmn.re.it |
| Italy | |
| Azienda Ospedaliera "Ospedale Civile di Legnano" | Recruiting |
| Legnano, MI, Italy, 20025 | |
| Contact: Stefano De Servi, MD stefano.deservi@ao-legnano.it | |
| Principal Investigator: Stefano De Servi, MD | |
| Arcispedale Santa Maria Nuova-IRCCS | Recruiting |
| Reggio Emilia, Italy, 42123 | |
| Contact: Stefano Savonitto, MD +39-0522-296361 stefano.savonitto@asmn.re.it | |
| Principal Investigator: Stefano Savonitto, MD | |
More Information
No publications provided
| Responsible Party: | StefanoSavonitto, dept of Cardiology - Arcispedale Santa Maria Nuova - IRCCS, Arcispedale Santa Maria Nuova-IRCCS |
| ClinicalTrials.gov Identifier: | NCT01777503 History of Changes |
| Other Study ID Numbers: | EudraCT Number: 2012-002882-37 |
| Study First Received: | January 21, 2013 |
| Last Updated: | January 24, 2013 |
| Health Authority: | Italy: Ethics Committee |
Keywords provided by Arcispedale Santa Maria Nuova-IRCCS:
|
acute coronary syndrome elderly percutaneous revascularization antiaggregant drugs |
Additional relevant MeSH terms:
|
Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Ischemia Acute Coronary Syndrome Arterial Occlusive Diseases Vascular Diseases Coronary Disease Heart Diseases Pathologic Processes Angina Pectoris Chest Pain Pain |
Signs and Symptoms Clopidogrel Prasugrel Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Pharmacologic Actions Purinergic P2Y Receptor Antagonists Purinergic P2 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013